Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Asset Writedowns and Impairment (2023 - 2024)

Autolus Therapeutics (AUTL) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $414000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Asset Writedowns and Impairment changed N/A year-over-year to $414000.0, compared with a TTM value of $414000.0 through Sep 2025, down 47.99%, and an annual FY2024 reading of $414000.0, up 8.38% over the prior year.
  • Asset Writedowns and Impairment was $414000.0 for Q2 2024 at Autolus Therapeutics, up from $382000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $414000.0 in Q2 2024 and bottomed at $382000.0 in Q3 2023.